Clinical research has shown that the recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab (Rituxan®, Genentech / Biogen Idec). These results were presented by… Continue
Added by Peter Hofland, PhD on June 10, 2011 at 6:00pm —
No Comments
Data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of the novel taxane cabazitaxel (Jevtana® ) was published in the October 2, 2010 print edition of… Continue
Added by Peter Hofland, PhD on October 1, 2010 at 11:30am —
No Comments